Literature DB >> 15486073

Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability.

Michele L Criscuoli1, Mai Nguyen, Brian P Eliceiri.   

Abstract

Vascular endothelial growth factor (VEGF)-induced vascular permeability (VP) is a hallmark of tumor growth and metastasis. Previous studies have shown a requirement for Src kinase in VEGF-mediated VP and signaling in blood vessels. In this study, we have examined the effect of Src-mediated reduced VP on tumor growth and metastasis. The growth and spontaneous metastasis of VEGF-expressing tumor cells were determined in Src-knockout (src(-/-)) or control mice (src(+/+) or src(+/-)). In comparison to control mice, src-null mice had a significant reduction in tumor-induced VP as well as a subsequent reduction in spontaneous metastasis. In contrast, primary tumor weight and vascular density were unchanged between src-null and control mice. Consistent with a role for Src in the extravasation of tumor cells from the circulation, direct intravenous injection of lung carcinoma cells resulted in a more than 2-fold reduction in lung tumor burden in src-null mice compared to control mice. The comparison of the results from the experimental metastasis and the spontaneous metastasis models suggests that there are defects in VP in the primary site of Src-deficient mice and that there may be an essential role for Src and Src-mediated VP in tumor metastasis to the lung.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486073     DOI: 10.1182/blood-2004-06-2246

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Perspective: The right trials.

Authors:  Patricia S Steeg
Journal:  Nature       Date:  2012-05-30       Impact factor: 49.962

Review 2.  Hemangioblasts representing a functional endothelio-hematopoietic entity in ontogeny, postnatal life, and CML neovasculogenesis.

Authors:  Gregor Prindull
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability.

Authors:  Ding Xu; Mark M Fuster; Roger Lawrence; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

4.  Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis.

Authors:  Ganapati H Mahabeleshwar; Weiyi Feng; Kumar Reddy; Edward F Plow; Tatiana V Byzova
Journal:  Circ Res       Date:  2007-07-19       Impact factor: 17.367

5.  Interaction of kindlin-2 with integrin β3 promotes outside-in signaling responses by the αVβ3 vitronectin receptor.

Authors:  Zhongji Liao; Hisashi Kato; Manjula Pandey; Joseph M Cantor; Ararat J Ablooglu; Mark H Ginsberg; Sanford J Shattil
Journal:  Blood       Date:  2015-01-13       Impact factor: 22.113

6.  Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.

Authors:  John C Morgan; John E Majors; Deni S Galileo
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

7.  Apoptosis-associated tyrosine kinase 1 inhibits growth and migration and promotes apoptosis in melanoma.

Authors:  Shuang Ma; Brian P Rubin
Journal:  Lab Invest       Date:  2014-03-03       Impact factor: 5.662

Review 8.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.

Authors:  M P Kim; S I Park; S Kopetz; G E Gallick
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

9.  Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells.

Authors:  Sardarpasha Sheikpranbabu; Kalimuthu Kalishwaralal; Deepak Venkataraman; Soo Hyun Eom; Jongsun Park; Sangiliyandi Gurunathan
Journal:  J Nanobiotechnology       Date:  2009-10-30       Impact factor: 10.435

10.  The innate immune system in host mice targets cells with allogenic mitochondrial DNA.

Authors:  Kaori Ishikawa; Noriko Toyama-Sorimachi; Kazuto Nakada; Mami Morimoto; Hirotake Imanishi; Mariko Yoshizaki; Shigemi Sasawatari; Mamoru Niikura; Keizo Takenaga; Hiromichi Yonekawa; Jun-Ichi Hayashi
Journal:  J Exp Med       Date:  2010-10-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.